Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Interview: Project & Portfolio Management for Pharma & Biotech
Read the full interview with Eric Towler, Therapeutic Area Lead, BioPharma Project Management, Bristol-Myers Squibb and gain insight into the latest PPM trends.
1. What are the latest PPM trends occurring in the pharmaceutical/biotech industry?
The latest trend seems to be the huge diversity in what is expected of a “PPM” practitioner in any one organization. Current expectations range from your basic bread-n-butter, PMP-certified PM to someone who is officially leading R&D matrix teams or portfolio groups. The bread-n-butter PM of yesteryears is almost certainly not enough; this job role does still exist but is mostly a dead-end career that tops out at AD level or lower. The skill sets vary tremendously based on the organization. For the more leadership/strategic roles, the technical PM know-how may not be important at all. Whatever the technical/strategic requirements, EQ is as important as ever if not more. The bottom line is that the depth and breadth of knowledge required for overall marketability is more difficult than ever.
2. What are the main mistakes Product & Portfolio Managers tend to make and one should avoid?
Getting too comfortable in a role is a common mistake. It’s easy to do what you have done for years but you won’t learn much and you will certainly become less marketable.
3. What do you consider the most burning issue to be discussed at the upcoming 10th Annual Project & Portfolio Management for Pharma & Biotech – East conference?
There is no one burning topic as far as I am concerned. However, I believe it is an opportunity for practitioners to see gaps in their knowledge base and develop a plan to fill that gap.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Strategize your Risk Management Plan in 2 steps
Read below the interview with Judy to reveal the latest trends in risk management and find out what are the most important steps towards strategizing your risk management plan.
A prescription of Quality and Efficiency in the right doses
Read below the interview with Ronan to understand the importance of balance between quality and efficiency and reveal which pitfalls to avoid.
10 ways to improve patient experience
Take a look at the inforgraphic about "10 ways to improve patient experience".